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Abstract
Background: This study was conducted to identify a recommended dose for S-1, used in combination with 40-Gy 
radiation.
Methods: Thirty patients, 15 each with stage III and IVA oral carcinoma, were enrolled. All patients received a total dose 
of 40-Gy. For the S-1 treatment, patients were given either the standard Japanese dose, calculated according to body 
surface area, or a reduced dose. Groups consisting of at least three patients were given S-1 according to one of 8 
regimens.
Results: Hematologic toxicity was mild and reversible. The most common nonhematologic toxicity was mucositis. At 
level 8 that was the standard S-1 dose for 5 days per week for 4 weeks, dose-limiting toxicity was observed when 2 
patients had grade 4 mucositis. This level was thus deemed the maximum tolerated dose for the regimen.
Conclusions: The recommended dose of S-1 with concurrent radiotherapy was the reduced dose of S-1 given for 5 
days per week, for 4 consecutive weeks. Preoperative S-1 and concurrent radiotherapy was well tolerate and feasible 
and warrants a phase II study.
Introduction
Today the treatment of primary oral squamous cell carci-
noma includes various combinations of radiotherapy,
chemotherapy and surgery. In literature searches, studies
employing adjuvant strategies of radiotherapy after sur-
gery outnumber those of preoperative concepts. Never-
theless, for about 20 years, preoperative therapy concepts
have been established as the standard approach in some
centers. Klug et al. summarized the results of the preop-
erative chemoradiotherapy for oral cancer [1]. He
r e p o r t e d  t h a t  5 - y e a r  s u r v i v a l  r a t e  d e t e r m i n e d  b y  t h e
meta-analysis of the 32 studies (1927 patients) was 62.6%,
appearing to be remarkably good.
Kirita et al. reported obtaining a clinical response rate
of 97.9%, and a 5-year overall actuarial survival rate of
81.3%, by treating advanced oral cancer with preoperative
concurrent cisplatin- or carboplatin-based intravenous
chemotherapy and radiotherapy at a total dose of 40-Gy
[2]. Iguchi et al. reported an overall response rate of 100%
when treating oral and maxillary carcinoma with concur-
rent chemoradiotherapy, using a combination of intraar-
terial pirarubicin, intravenous continuous 5-fluorouracil
(5-FU), and a radiation dose of 40-Gy [3]. They con-
cluded that their concurrent chemotherapy regimen is
effective as a preoperative modality, with a remarkably
high response rate and an acceptable level of adverse
events.
S-1 is an oral fluoropyrimidine preparation that con-
sists of tegafur, 5-chloro-2, 4-dihydroxypyridine (gimera-
cil), a dihydropyrimidine dehydrogenase (DPD) inhibitor,
and potassium oxonate (oteracil), which inhibits orotate
phosphoribosyl transferase in the gastrointestinal tract,
thereby reducing the gastrointestinal toxicity of 5-FU [4].
A preclinical study showed that gimeracil, a DPD inhibi-
tor, is a potent radiosensitizing agent [5]. Preclinical stud-
ies using human oral cancer xenograft models showed a
better response from a combination of S-1 and fraction-
ated radiotherapy than from either treatment alone [6].
* Correspondence: hiro-harada.osur@tmd.ac.jp
1 Department of Oral Surgery, Oral Restitution, Division of Oral Health Sciences, 
Graduate School, Tokyo Medical and Dental University, Japan
Full list of author information is available at the end of the articleHarada and Omura Journal of Experimental & Clinical Cancer Research 2010,
29:33
Page 2 of 6
Here, we report a phase I study of S-1 chemotherapy
performed concomitantly with a radiation dose of 40-Gy
as the preoperative treatment for oral squamous cell car-
cinoma. The purpose of this study was to identify the
maximum tolerated dose (MTD) of S-1 in combination
with 40-Gy radiation, the dose-limiting toxicity (DLT) of
S-1, and the recommended dose (RD) for this treatment.
Patients and Methods
Patient eligibility
Previously untreated patients with histopathologically
proven oral squamous cell carcinoma of stage III or IVA
were evaluated for this study. Eligible patients were
required to be from 20 to 75 years old, have an Eastern
Cooperative Oncology Group performance status of 0 or
1, life expectancy of at least 3 months, and adequate
organ function (leukocytes  4000/mm3, platelets 
100,000/mm3, hemoglobin level  9.0 g/dl, aspartate
aminotransferase (AST) level  2 times the upper normal
limit (UNL), alanine aminotransferase (ALT) level  2
times the UNL, alkaline phosphatase (ALP) level  2
times the UNL, serum bilirubin  1.5 mg/dl, and serum
creatinin  the UNL.
Patients were excluded if they had received any prior
systemic chemotherapy or radiotherapy, had a concomi-
tant malignancy, active inflammatory bowel disease,
active gastric/duodenal ulcer, active infection, severe
heart disease, mental disorder, or other severe concurrent
disease. Pregnant or lactating females were also excluded.
The protocol was approved by the Institutional Review
Board of Tokyo Medical and Dental University. All
patients gave written informed consent before entry into
this study.
Treatment
We gave a fractional daily dose of 2-Gy for 5 days a week
to a total dose of 40-Gy using a 4-MV LINAC to deliver
X-rays to the primary tumor site, and if the patients had
nodal disease, to the cervical nodes (Figure 1).
S-1 (Taiho Pharmaceutical Co., Tokyo, Japan) was
administered orally twice a day after meals, concomitant
with radiotherapy. Each capsule of S-1 contained either
20 or 25 mg of tegafur, and individual doses, calculated
according to body surface area (BSA), were rounded
down to the nearest pill size. The dosing of S-1 was as fol-
lows (standard dose, reduced dose): BSA < 1.25 m2, 80 mg
or 50 mg daily; BSA  1.25 m2 but < 1.5 m2, 100 mg or 80
mg daily; BSA  1.5 m2, 120 mg or 100 mg daily. S-1 was
administered to patients on 5 consecutive days per week,
following the schedules shown (Figure 1).
Adverse events were evaluated according to the
National Cancer Institute Common Toxicity Criteria,
version 2.0. Hematological DLT was defined as grade 4
leukopenia or neutropenia, grade 3 febrile neutropenia,
or grade 3 thrombocytopenia. Nonhematologic DLT was
defined as grade 4 mucositis, or grade 3 or 4 nonhemato-
logical toxicities (excluding nausea/vomiting). The dosing
plan was, if none of 3 patients in a treatment group expe-
rienced DLT at a given dose level, the dose of S-1 was
escalated in the next cohort of 3 patients. If one of the ini-
tial 3 patients experienced DLT, 3 patients were added at
the same dose level. Dose escalation continued if DLT
was observed in only one of 6 patients. If 2 or more
patients experienced DLT at the dose level, the dose of
that level would be the MTD.
Our initial protocol consisted of dosing schedules to
level 6 (Figure 1) in September 2002, but no DLT was
observed even at level 6. Therefore, we added levels 7 and
8 in January 2005. Meanwhile, three patients were
enrolled in level 6. Consequently level 6 consisted of six
patients. In determining the RD, we considered the prac-
tical aspects of administering S-1 in addition to the mani-
festations of toxicity.
Treatment evaluation
All patients underwent surgery after chemoradiotherapy,
but the follow-up periods were not adequate for treat-
ment effects. Therefore, we judged the clinical efficacy of
the chemoradiotherapeutic protocol immediately just
before surgery. The median interval between the end of
chemoradiotherapy and surgery was 26.0 days (range, 15-
48 days).
The evaluation methods included computed tomogra-
phy (CT) scan, magnetic resonance imaging (MRI), and
ultrasound. Responses at the primary site and the neck
were analyzed separately. Treatment effects were esti-
mated based on changes in tumor size. A complete
response (CR) was defined as the complete clinical and
radiologic disappearance of the primary tumor. The neck
response was deemed complete with the disappearance
of any adenopathy, as determined using CT and ultra-
sound. A partial response (PR) was characterized as a
Figure 1 Administration schedule.
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50% or greater decrease in the product of two perpendic-
ular diameters of the primary and regional tumors by the
time of surgery. Stable disease (SD) was defined as a
tumor reduction of less than 50%. Progressive disease
(PD) was indicated by an increase of 25% or more in the
volume of any tumor or the appearance of new lesions.
For the histological evaluation of primary tumors, we
used Shimosato's classification of therapeutic effective-
ness [7]. Grade 0 indicates no noticeable change; grade I,
minimal cellular changes present, but the majority of
tumor cells appear viable; grade IIa, despite the presence
of cellular changes and partial destruction of the tumors,
the tumor is still readily recognizable, and a many tumor
cells appear viable; grade IIb, the tumor destruction is
extensive, but viable cell nests are present in small areas
of the tumor (one-quarter of the tumor mass, excluding
areas of coagulation necrosis); grade III, only a few scat-
tered, markedly altered, presumably nonviable tumor
cells are present, singly or in small clusters, and few or no
viable cells are seen; grade IV, no tumor cells remain in
any section.
Statistical Analysis
Survival time was assessed from the first day of treatment
until death or the last patient contact. Overall survival
and cumulative survival rates were calculated according
to the Kaplan-Meier method [8].
Results
Patient characteristics
Thirty patients, 24 men and 6 women, were enrolled in
this study between September 2002 and January 2007.
Their median age was 58.5 years (range, 32-75 years) and
their ECOG score was 0 for 29 patients and 1 for a
patient. The primary lesion sites were the tongue (n = 10),
the floor of the mouth (n = 4), the upper gum (n = 5), the
lower gum (n = 9), and the buccal mucosa (n = 2). The
T N  c l a s s i f i c a t i o n  i s  s h o w n  i n  T a b l e  1 .  F i f t e e n  p a t i e n t s
each had stage III or IVA carcinomas. The median fol-
low-up period was 67 months (range 37-89 months).
Toxicity
Cases with toxicities observed during treatment or within
2 weeks after chemoradiotherapy are listed in Additional
file 1. Grade 1-2 leukocytopenia was observed in 46.7% (n
= 14) of the patients. Neutropenia was rare; grade 1-2
neutropenia occurred in 5 patients (16.7%). Grade 1 ane-
mia was observed in 60% (n = 18) of the patients and
grade 1 elevated AST in 40% (n = 12). For all treatment
levels, the hematologic toxicity was grade 1 or 2. Gener-
ally, the hematologic toxicity was mild and reversible, and
there was no grade 3 or 4 hematologic toxicity.
Nonhematological toxicities, apart from mucositis,
were grade 1 or 2, and the most common was mucositis.
Grade 1 or 2 mucositis was observed at treatment levels
1-4. Although 11 patients (36.7%) had grade 3 mucositis,
there was no DLT at levels 1-7. One of three patients
experienced a DLT (grade 4 mucositis) at level 8: based
on the results, three additional patients were added, one
DLT was seen. Consequently, 2 DLTs were observed
among 6 patients at level 8, thus the doses used level 8
were deemed the MTD in this study. Therefore, we pro-
pose the level 7, the reduced S-1 dose 5 days per week for
4 weeks, as the RD.
Efficacy
The clinical responses of the primary tumors are shown
in Table 2. Three patients achieved CR and 25 achieved
PR. The overall clinical response rate (CR or PR) was
93.3%. The histological evaluation was grade IV (no via-
ble tumor cells in any section) in 2 patients (Table 3) and
grade III in 13. The histological response rate, defined as
grades of IIb, III, or IV, was 90.0%.
Clinical responses of neck metastases are shown in
Table 4. Nine patients showed clinical PR, 10 showed SD,
and 2 showed PD. The clinical response rate (CR or PR)
of the neck disease was 42.9%.
After surgery, local failure developed in one patient
(level 6), and neck failure and distant metastasis occurred
in another (level 7). With a median follow-up of 67
months, the 5-year overall survival rate was 90.0%, and
the 5-year cumulative survival was 93.1%.
Discussion
We set out to determine the safety and reliability of con-
current S-1 and radiotherapy in advanced cancer of the
oral cavity, in a phase I study. Many studies have demon-
strated that combined chemotherapy and radiation is a
Table 1: TN classification
T2 T3 T4a Total
N 0 0729
N1 5 3 2 10
N2b 2 4 3 9
N2c 0 0 2 2
Total 7 14 9 30Harada and Omura Journal of Experimental & Clinical Cancer Research 2010,
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highly effective treatment modality for increasing the
survival of patients with advanced disease [2,3,9-11].
Concurrent chemoradiotherapy has been established as
an appropriate standard for many patients with locally
advanced head and neck cancer.
To the best of our knowledge, this study is the first trial
of S-1 and radiotherapy in oral cancer. Tsukuda et al.
reported that most adverse events of S-1 administration
alone were hematological, gastrointestinal, and skin tox-
icities, although most of these were grade 1 or 2 and con-
trollable [12]. In the present study, there was no severe
hematological, gastrointestinal, or skin toxicity. Mucositis
was the most common adverse event, with grade 3
mucositis observed in 66.7% of patients at levels 5, 6, and
7 (Additional file 1). Grade 4 mucositis, constituting DLT,
was observed in 2 of 6 patients at level 8. The doses used
level 8 was deemed the MTD. Therefore, the determined
recommended dose of S-1 was the reduced dose for 5
days per week for 4 weeks (level 7).
In a multi-institutional cooperative late phase II clinical
study of S-1 alone in patients with advanced/recurrent
head and neck cancer in Japan, the clinical response rate
of the primary tumor was 36.4% in oral cancer patients
[13]. In the present study, the overall clinical response
rate was 93.3%, and the histological response rate was
90.0%, appearing to be remarkably good.
Many studies have demonstrated concurrent chemora-
diotherapy to be effective in patients with advanced head
and neck cancer. However, the majority of studies have
reported total radiation doses of more than 60-Gy. Tsu-
kuda et al. reported that the complete response rate were
93% in stage III and 54% in stage IV, by treating head and
neck cancer with S-1 and radiotherapy at a total dose of
66-70.2 Gy [14]. There have been few reports on the
Table 2: Clinical response of the primary tumors
CR PR SD PD Response rate
Level 1 3 100%
Level 2 1 2 100%
Level 3 1 2 100%
Level 4 3 100%
Level 5 3 100%
Level 6 4 2 66.7%
Level 7 3 100%
Level 8 1 5 100%
Total 3 25 2 0 93.3%
Abbreviations: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease
Table 3: Histologic evaluation of the primary tumors after chemoradiotherapy
IV III IIb IIa I Response 
rate
Level 1 2 1 100%
Level 2 1 2 100%
Level 3 2 1 100%
Level 4 1 2 100%
Level 5 1 2 100%
Level 6 4 1 1 66.7%
Level 7 1 1 1 66.7%
Level 8 3 3 100%
Total 2 13 12 2 1 90.0%
*The histological evaluation was defined according to Shimosato's classification of therapeutic effectivenessHarada and Omura Journal of Experimental & Clinical Cancer Research 2010,
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effect of preoperative chemoradiotherapy with a total
radiation dose of 40-Gy [2,3].
Osteoradionecrosis of the jaw is one of the serious
complications of radiotherapy for head and neck cancer.
High-dose radiotherapy for oral cancer induces mandibu-
lar osteoradionecrosis with an incidence of approximately
5% to 20% [15,16]. The management of osteoradionecro-
sis is difficult and not always successful. Therefore, if the
antitumor effect could be increased by combining che-
motherapy with lower doses of radiotherapy, it might
reduce radiation-related adverse events without sacrific-
ing efficacy. The combined method studied here has the
potential to increase the antitumor effect while minimiz-
ing surgery. Therefore, a phase II study is warranted.
On the other hand, the clinical response rate for neck
nodal disease was 42.9%. This result was poor compared
with the clinical response rate of the primary tumor. A
late phase II clinical study of S-1 alone found a clinical
response rate was 21.7% for cervical lymph node metasta-
sis [13]. These results have suggested that neck dissection
is warranted for metastatic lymph nodes in patients with
oral carcinoma.
In conclusion, the concurrent administration of S-1 and
radiotherapy was well tolerated and yielded sufficiently
positive results. The RD of S-1 with concurrent radio-
therapy for this protocol is BSA <1.25 m2, 50 mg/day;
BSA 1.25-1.5 m2, 80 mg/day; BSA ≥ 1.5 m2, 100 mg/day
for 5 days per week for 4 weeks. We have already started a
phase II study in multiple institutes.
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